Enovis Raises 2026 Profit Outlook as Q3 Organic Sales Rise 5%

Enovis Corporation (NYSE: ENOV) raised its full-year 2026 adjusted EBITDA and adjusted earnings guidance after third-quarter organic sales growth, wider margins and stronger free cash flow. Reconstructive products led the quarter, while the divestiture of Dr. Comfort weighed on reported growth in the Prevention & Recovery segment.

For the three months ended October 2, net sales increased 1.8% to $558.7 million from $548.9 million a year earlier. Organic sales rose 5%, including 6% growth in Reconstructive and 3% in Prevention & Recovery.

Adjusted EBITDA increased to $103.5 million from $94.8 million, lifting the adjusted EBITDA margin to 18.5% from 17.3%. Adjusted gross margin expanded to 60.9% from 60.3%, while adjusted diluted earnings per share rose to $0.88 from $0.75.

On a GAAP basis, Enovis reported net income of $3.4 million, compared with a $570.9 million loss in the prior-year quarter, which included a $548.4 million goodwill impairment charge. Third-quarter 2026 results included $43.3 million of acquired-intangible amortization and $15.6 million of strategic transaction costs.

For the first nine months of 2026, revenue rose 3.5% to $1.73 billion. Adjusted EBITDA increased to $311.4 million from $273.0 million, and the adjusted EBITDA margin widened to 18.0% from 16.3%. Adjusted EPS advanced to $2.67 from $2.12.

Reconstructive growth leads segment performance

Reconstructive segment sales increased 6% on both a reported and organic basis to $273.3 million. Global Extremities sales grew 8%, while Hip and Knee sales increased 5%.

U.S. Reconstructive organic growth was 5%, including 5% growth in Extremities, led by Shoulder, and 3% growth in Hip and Knee. International Reconstructive organic sales rose 8%, supported by double-digit Shoulder growth and product launches including the ARVIS augmented-reality system.

Enovis said it continued to invest in technologies including Nebula, the OrthoDrive Impactor and ARVIS. The company also has a pending acquisition of eCential Robotics, whose surgical robotics platform is expected to complement ARVIS. Completion timing, funding, integration and the acquisition’s potential financial and operational effects remain subject to uncertainty.

Prevention & Recovery sales declined 1.9% on a reported basis to $285.4 million, primarily reflecting the Dr. Comfort divestiture, but rose 3% organically. Global Bracing grew 3%, while U.S. organic sales increased 5%. Enovis cited Bone Growth Stimulation, MotionMD penetration, and core Knee and Lower Extremity bracing as key growth drivers, supported by reimbursement conditions and commercial execution. The company is also investing in the ManaFuse Bone Growth Stimulator.

Profit outlook raised as cash generation improves

Enovis now expects full-year adjusted EBITDA of $428 million to $438 million, compared with its August range of $425 million to $435 million. Adjusted EPS is projected at $3.58 to $3.79, up from the previous $3.52-to-$3.73 range.

The company narrowed its reported revenue forecast to $2.32 billion to $2.35 billion from $2.31 billion to $2.37 billion. Its outlook assumes approximately 5% organic growth, a foreign-exchange benefit of 0.5% to 1.0%, high-single-digit Reconstructive growth and low-single-digit Prevention & Recovery growth. The Dr. Comfort divestiture is expected to reduce reported revenue growth by 1.8 percentage points, or about $41 million.

Updated profit assumptions include a $15 million benefit from a 2025 tariff refund, partly offset by a $10 million impact from Middle East conditions and higher inflationary pressures. Accelerated enabling-technology investments and current foreign-exchange rates could have an additional negative impact of up to $5 million. Management also expects normal procedural seasonality through the fourth quarter against softer Western European volumes and the Middle East conflict.

Free cash flow totaled $35 million in the quarter, up from $29.1 million a year earlier. Nine-month free cash flow improved by nearly $50 million to $37.3 million from negative $12.4 million. Enovis said it remains on track for free-cash-flow conversion above 25% in 2026, supported by operating leverage, asset efficiency and lower one-time EU Medical Device Regulation and other adjusted costs.

At quarter-end, Enovis had $1.3 billion of total debt, $958 million of unused revolving-credit capacity and trailing-12-month leverage of 2.9 times. The company also authorized up to $200 million of share repurchases while maintaining organic investment, debt repayment and selective portfolio transactions among its capital-allocation priorities.

Risks identified by Enovis include acquisition and integration execution, tariffs and changing trade policies, inflation, supply-chain disruption, geopolitical conflicts, weaker Western European procedure volumes, and energy costs and availability, particularly in Europe.